PHOSPHORUS-32 LABELING OF ANTIBODIES FOR CANCER THERAPY

摘要

Recombinant fusion proteins containing at least one domain which confers targeting properties on the fusion protein, together with at least one peptide sequence that is a substrate for a protein kinase, can be labeled with ?32P or 33¿P by treatment with a protein kinase and a ?32P- or 33¿P-labeled phosphate donor. The labeled targeting proteins bind specifically to diseased cells or tissue, which are killed by the radiation from the ?32P or 33¿P.